I wasn't expecting much today but all these small moves add up.
While our HCV programs are in their infancy, maybe we can catch some of that HCV bubble if we move to the US.
We'll have a lead candidate for our NN in June. For the non-NN side we have power to destroy Biocrysts program (which is about to start clinical trials at the end of the year). If we have power to destroy something then we can control it lol. If US investors liked Biocrysts HCV program so much that it bid up it's MC by $100M then by extension our patent has the goods.
To illustrate the HCV bubble, Novartis handed over upfront $30 million for a pre-clinical HCV candidate.
Invivo Blog
- Forums
- ASX - By Stock
- BTA
- how will management play down this news
how will management play down this news, page-9
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online